Back

Leading experts in nephrology react to how the FDA approval of pegcetacoplan (Empaveli) shifts treatment discussions for patients with C3 glomerulopathy.

RX Review: Updates and Unmet Needs in C3G—The Role of Pegcetacoplan

Episodes

Specialty:

All

Year:

All

Thumbnail for RX Review: Updates and Unmet Needs in C3G—The Role of Pegcetacoplan

EP. 1: A New Era for C3G Treatment with Pegcetacoplan

ByShikha Wadhwani, MD, MS,Anuja Java, MD,Corey Cavanaugh, DO

August 5th 2025

In part 1 of this 5-part HCPLive RX Review, experts discuss the current therapeutic landscape for C3G following 2 notable FDA approvals.

EP. 2: Navigating Targeted Therapies for C3 Glomerulopathy

ByShikha Wadhwani, MD, MS,Anuja Java, MD,Corey Cavanaugh, DO

August 5th 2025

In part 2 of this 5-part HCPLive RX Review, experts discuss how to utilize the newly FDA-approved therapies for treating C3G and what questions remain.

EP. 3: Understanding Pegcetacoplan in C3G with VALIANT Data

ByShikha Wadhwani, MD, MS,Anuja Java, MD,Corey Cavanaugh, DO

August 5th 2025

In part 3 of this 5-part HCPLive RX Review, experts discuss VALIANT data supporting pegcetacoplan’s approval and how they compare to iptacopan.

EP. 4: Approaching Incident C3G in an Era of Targeted Therapies

ByShikha Wadhwani, MD, MS,Anuja Java, MD,Corey Cavanaugh, DO

August 5th 2025

In part 4 of this 5-part HCPLive RX Review, experts discuss how the availability of new therapeutic options are changing the treatment paradigm in C3G.

EP. 5: Unmet Needs and Unanswered Questions in C3G

ByShikha Wadhwani, MD, MS,Anuja Java, MD,Corey Cavanaugh, DO

August 5th 2025

In the final segment of this 5-part HCPLive RX Review, experts discuss real-world barriers to implementing new C3G therapies and lingering unmet needs.